191599-51-6

Usage

Uses

Used in Pharmaceutical Industry:
1,3-Piperidinedicarboxylic acid, 1-(1,1-dimethylethyl) 3-ethyl ester, (3S)(9CI) is used as a building block in the synthesis of various drugs due to its medicinal properties. Its unique structure and chirality allow for the development of new pharmaceutical compounds with potential therapeutic effects.
Used in Chemical Synthesis:
1,3-Piperidinedicarboxylic acid, 1-(1,1-dimethylethyl) 3-ethyl ester, (3S)(9CI) serves as a starting material for the preparation of other chemical compounds. Its versatile structure enables the synthesis of a wide range of molecules with diverse applications in various industries.
Used in Drug Discovery:
1,3-Piperidinedicarboxylic acid, 1-(1,1-dimethylethyl) 3-ethyl ester, (3S)(9CI) may have potential biological activity that can be explored for various applications. Its chiral nature and unique structure make it a promising candidate for drug discovery, where it can be further modified and optimized to target specific biological pathways or receptors.

InChI:InChI=1/C13H23NO4/c1-5-17-11(15)10-7-6-8-14(9-10)12(16)18-13(2,3)4/h10H,5-9H2,1-4H3/t10-/m0/s1

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 37675-18-6 (S)-(+)-nipecotic acid ethyl ester 
• 498-95-3 (S)-nipecotic acid 

Downstream Products

• 88495-54-9 (3S)-1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid 
• 140695-84-7 tert-butyl (3S)-3-(hydroxymethyl)piperidine-1-carboxylate 
• 278789-43-8 ethyl N-t-butyloxycarbonyl-3-methylpiperidine-3-carboxylate 
• 6874-86-8 (–)-castoramine 
• 1008563-06-1 (S)-3-acetyl-piperidine-1-carboxylic acid tert-butyl ester 
• 1002359-83-2 (R)-3-(hydrazinecarbonyl)piperidine-1-carboxylic acid tert-butyl ester 
• 1008563-08-3 (S)-3-[1-(2-formyl-phenoxy)-1-methyl-ethyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 140645-23-4 1,1-dimethylethyl (3R)-3-(aminomethyl)-1-piperidinecarboxylate 
• 140645-22-3 (3S)-3-azidomethyl-1-(tert-butoxycarbonyl)-piperidine 
• 191092-08-7 tert-butyl (3S)-3-[[(4-methylbenzenesulfonyl)oxy]methyl]piperidine-1-carboxylate 
• 37675-19-7 (S)-piperidine-3-carboxylic acid ethyl ester hydrochloride 
• 384830-06-2 (2S,3R)-3-((R)-1-{Benzyloxycarbonylamino-[(E)-benzyloxycarbonylimino]-methyl}-piperidin-3-ylmethyl)-4-oxo-1-[4-(6-phenyl-hexanoyl)-piperazine-1-carbonyl]-azetidine-2-carboxylic acid benzyl ester 
• 384830-05-1 (2S,3R)-3-((R)-1-{Benzyloxycarbonylamino-[(E)-benzyloxycarbonylimino]-methyl}-piperidin-3-ylmethyl)-4-oxo-azetidine-2-carboxylic acid benzyl ester 
• 384830-02-8 (R)-3-((2S,3R)-2-Benzyloxycarbonyl-4-oxo-azetidin-3-ylmethyl)-piperidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

One-Pot Reductive Allylation of Amides by Using a Combination of Titanium Hydride and an Allylzinc Reagent: Application to a Total Synthesis of (-)-Castoramine

A one-pot direct reductive allylation protocol has been developed for the synthesis of secondary amines by using titanium hydride and an allylzinc reagent. This protocol is applicable to a broad range of substrates, including acyclic amides, benzamides, α,β-unsaturated amides, and lactams. The stereochemical outcome obtained from the reaction with crotylzinc reagent suggested that the allylation reaction proceeds through a six-membered cyclic transition state. A total synthesis of (-)-castoramine was accomplished by following this protocol for the highly stereoselective construction of contiguous stereocenters.

Novel Triazolopyrazine Derivatives and Use Thereof

The present invention relates to novel triazolopyrazine derivatives or a pharmaceutically acceptable salt, and a pharmaceutical composition for inhibiting c-Met tyrosine kinase activity and a pharmaceutical composition for preventing or treating hyperproliferative disorders, containing the same as active ingredients. The present invention effectively inhibits c-Met tyrosine kinase activity, thereby being able to be useful as a drug for various hyperproliferative disorders such as cancers, psoriasis, rheumatoid arthritis, diabetic retinitis, etc. related to excessive cell proliferation and growth by abnormal kinase activation.

NOVEL TRIAZOLOPYRAZINE DERIVATIVE AND USE THEREOF

The present invention relates to a novel triazolopyrazine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating hyper proliferative disorder. The present invention can be useful as a therapeutic agent for various hyper proliferative disorders associated with excessive cell proliferation and growth caused by abnormal kinase activity, such as cancer, psoriasis, rheumatoid arthritis, and diabetic retinopathy, by efficiently inhibiting c-Met tyrosine kinase activity.

ISOXAZOLE DERIVATIVES AS MODULATORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1

The present invention relates to novel isoxazole compounds of formula (I), and pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides thereof, which are modulators of 11?-hydroxysteroid dehydroge

4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: Design, synthesis and structure-activity relationships

Single enantiomer [(aryloxy)(pyridinyl)methyl]piperidine and pyrrolidine derivatives 5-9 are inhibitors of monoamine reuptake. Structure-activity relationships established that monoamine reuptake inhibition are functions of amine, pyridine isomer, aryloxy ring substitution and stereochemistry. Consequently, selective NRIs, selective SRIs, dual SNRIs and triple SNDRIs were all identified. Dual SNRIs 5l-a and 9c were evaluated in additional pharmacology and pharmacokinetic studies as representative examples from this series.

FARNESYL PROTEIN TRANSFERASE INHIBITORS

Disclosed are compounds of formula (1.0), wherein R represents a cyclic moiety to which is bound an imodazolylalkyl group; R represents a carbamate, urea, amide or sulfonamide group; and the remaining substituents are as defined herein. Also disclosed is a method of treating cancer and a method of inhibiting farnesyl protein transferase using the disclosed compounds.

Synthesis of potent and highly selective inhibitors of human tryptase

The serine protease tryptase has been implicated in allergic and inflammatory diseases and associated with asthma. The synthesis and SAR of a series of N1-activated-4-carboxy azetidinones are described, resulting in identification of BMS-363131 (2) as a potent inhibitor of human tryptase (IC503000-fold) for tryptase versus related serine proteases including trypsin.

Beta lactam compounds and their use as inhibitors of tryptase

Compounds of the formulas: are disclosed. These compounds inhibit tryptase as well as other enzyme systems or are selective tryptase inhibitors and are useful as antiinflammatory agents particularly in the treatment of chronic asthma.

Oligomers of β2- and of β3-homoproline: What are the secondary structures of β-peptides lacking H-bonds?

To study the role of H-bonds in stabilizing β-peptidic secondary structures, we have synthesized β-oligopeptides (up to the octadecamer 12) consisting of β2- and β3-homoproline, i.e., β-peptides lacking amide protons. The enantiomer purity of the building block β2-homoproline (nipecotic acid, 4) was determined by HPLC analysis of the N-(2,4- dinitrophenyl) derivative 5 on a Chiralcel-OD column (cf. Fig. 2). The CD spectra of the all-(S)-β2- and all-(S)-β3-HPro-containing, β-peptides display novel and intensive CD patterns which may be indicative of a secondary structure (cf. Fig. 3). It is noteworthy that a distinct CD pattern was observed with the β3-HPro derivatives containing as few as three residues (7a). The crystal structure of a N-deprotected β3-HPro-tripeptide 7c is presented (cf. Figs. 4 and 5), and a model for the structure of β- peptides consisting of β3-HPro is discussed (cf. Figs. 6 and 7).

INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.